Infinite IoT: Is IoT Broken?

IoT is an acronym for the Internet of Things. According to iTech Post, “it describes devices that connect to the internet to send and receive information. IoT is similar to artificial intelligence (AI) in that it enables machines to perform certain tasks.” In general, we are interacting with AI more than we realize, and up to “50 times a day,” said Mike Mulica, CEO of Alef. But to fully scale IoT to an enterprise level, the structure of the market model must change.

“Major carriers of 5G are not moving fast enough,” Mulica said. Mobile operators operate from a centralized market model, which is not conducive to the way enterprises use it. “The enterprise has a sophisticated view of what they need,” Mulica said. “They look at things from a business enterprise-centric perspective.”

First, let’s consider the cost hurdle. When it comes to the cost of running enterprise-level mobility that’s needed to operate IoT on an enterprisescale, the cost of setting up that mobility is a huge investment. According to a 2018 Forbes article, “the high costs of IoT has significantly slowed down mass adoption.” Mulica recommended that the cost be lowered to the point where it’s like adopting Wi-Fi.

IoT would also be more adaptable if it were as easy to set up as Wi-Fi. With Wi-Fi, once you have the router plugged in and turned on, it’s almost immediate connectivity. That connectivity is not comparable in enterprise mobility. Enterprises do not have the operations needed, the logistics of a mobile operator in-house and ready to deploy their IoT.

In summary, “it’s not unusual for the average consumer to require an expert service provider to make sure that their devices are on their network and functioning properly,”according to Forbes. Once mobile operators shift from privatized networks, IoT will experience growth, opportunity, and enormous benefits for enterprises. Mulica explains that IoT can be compared to more standard technology, like the cloud.“The main value of the cloud, the cloud itself, is the value,”he said. Simply put, enterprises don’t have the mobile DNA to replicate what the mobile operators have been able to do. Lowering the threshold of expertise and creating an open model is the best way forward

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More